Research programme: injectable insulin formulations - AntriaBio

Drug Profile

Research programme: injectable insulin formulations - AntriaBio

Alternative Names: AB 102; insulin sustained-release

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PR Pharmaceuticals
  • Developer AntriaBio
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC, Injection)
  • 05 Jun 2017 AntriaBio plans a first-in-human, phase I trial to evaluate the safety, pharmacokinetics and time-action profile of single ascending doses of AB 101, for Type 1 diabetes mellitus in USA
  • 01 May 2017 AntriaBio announces intention to submit IND to US FDA for Type 1 diabetes mellitus in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top